Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

San Cugat del Valles, Spain Clinical Trials

A listing of San Cugat del Valles, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (82) clinical trials

PMCF-study Using Novosyn Quick Suture Material for Perineal Repair After Episiotomy

The aim of this study is to show that the performance of Novosyn Quick suture material is comparable with other suture material used for episiotomy. In order to show that, various safety and efficacy parameters have been selected. The outcome regarding these parameters will be evaluated by a quantitative summary ...

Phase N/A

0.0 miles

Learn More »

Observational Post-Authorisation Study on the Use of Bemfola in Human Assisted Reproductive Techniques in Spain.

Non-comparative, observational, ambispective post-authorisation study (EPA-SP).

Phase N/A

2.76 miles

Learn More »

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GDC-9545 as a single agent and in combination with palbociclib and/or luteinizing hormonereleasing hormone (LHRH) agonist in participants with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.

Phase

3.77 miles

Learn More »

Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer

Patients must have received at least one previous regimen in the advance disease setting and must have at least one measurable lesion that can be accurately assessed according to RECIST v.1.1. Potential eligible patients will be screened to assess somatic (s) BRCA promoter methylation at an reference central laboratory. Germinal ...

Phase

3.77 miles

Learn More »

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

Recent decades have witnessed a delay in childbearing for a variety of reasons including cultural, educational, and professional. As a consequence, breast cancer in young women often occurs before the completion of reproductive plans. Infertility has a significant impact on quality of life, resulting in substantial distress in younger women ...

Phase N/A

3.77 miles

Learn More »

Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study involves patients receiving a NMA lymphocyte depleting preparative regimen, followed ...

Phase

3.77 miles

Learn More »

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO]

Patients with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized to selinexor or placebo until disease progression.

Phase

3.77 miles

Learn More »

A Clinical Study of Cobimetinib Administered in Combination With Niraparib With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

The study will include a safety run-in phase (Stage 1) and a randomization phase (Stage 2). The purpose of Stage 1 is to evaluate the safety of cobimetinib when administered in combination with niraparib (Cohort 1) and cobimetinib with niraparib plus atezolizumab (Cohort 2). Stage 1 will enable patient enrollment ...

Phase

3.77 miles

Learn More »

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Pre- and post-menopausal women age 18 years with HR-positive and HER2-negative with ABC that had previously received first-line endocrine therapy in combination with palbociclib and had achieved clinical benefit during palbociclib-based treatment. Patients relapsing on a palbociclib-based regimen in the adjuvant setting are also eligible. Patients are not eligible if ...

Phase

4.16 miles

Learn More »

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

This study is designed as a randomized, active-controlled, superiority study in patients with unresectable locally advanced or metastatic HER2-positive breast cancer. The patients should have had either progression during or after at least two HER2-targeting treatment regimens for locally advanced or metastatic disease or progression during or after (ado-)trastuzumab emtansine ...

Phase

4.46 miles

Learn More »